Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | BCHE | P06276 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11891125 | 0.91 | KDM4E (0.55) | KDM4ESMN1; SMN2MAPTCYP1A2CYP3A4 | |
| SCHEMBL23118938 | 0.89 | KDM4E (0.53) | KDM4ESMN1; SMN2MAPTCYP1A2CYP3A4 | |
| SCHEMBL18714136 | 0.88 | KDM4E (0.52) | KDM4ESMN1; SMN2MAPTCYP1A2CYP3A4 | |
| SCHEMBL18466595 | 0.88 | KDM4E (0.52) | KDM4ESMN1; SMN2MAPTCYP1A2CYP3A4 | |
| Avanbulin SCHEMBL1160317 | 0.88 | KDM4E (0.56) | KDM4ESMN1; SMN2MAPTCYP1A2CYP3A4 | |
| Avanbulin SCHEMBL29374555 | 0.88 | KDM4E (0.56) | KDM4ESMN1; SMN2MAPTCYP1A2CYP3A4 | |
| Avanbulin SCHEMBL9099635 | 0.87 | KDM4E (0.55) | KDM4ESMN1; SMN2MAPTCYP1A2CYP3A4 | |
| SCHEMBL17826523 | 0.85 | ALDH1A1 (0.55) | KDM4ESMN1; SMN2MAPTCYP1A2CYP3A4 | |
| SCHEMBL11890502 | 0.84 | KDM4E (0.73) | KDM4ESMN1; SMN2MAPTBCHETP53 | |
| SCHEMBL1160486 | 0.83 | KDM4E (0.58) | KDM4ESMN1; SMN2MAPTCYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE42890-E1 | Furazanobenzimidazoles | BASILEA PHARMACEUTICA AG (CH) | 2011-11-01 | — | — | US | disclosed |
| US-7385061-B2 | 4-[1-(6-amino-3-pyridylcarbonylmethyl)-1H-benzimidazol-2-yl]-furazan-3-yl]-N-(2-cyanoethyl)-amine; treatment of neoplastic and autoimmune diseases | BASILEA PHARMACEUTICA AG (CH) | 2008-06-10 | — | — | US | disclosed |
| EP-1636215-B1 | FURAZANOBENZIMIDAZOLES | BASILEA PHARMACEUTICA AG (CH) | 2008-01-23 | — | — | EP | disclosed |
| US-20070043061-A1 | Furazanobenzimidazoles | BASILEA PHARMACEUTICA AG | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043061-A1 | Furazanobenzimidazoles | FOXO1, CYP2F1, OXER1 | KDM4E 1039/4885SMN1; SMN2 2831/4885MAPT 4783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.